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Background and Purpose The benefit of statins in acute stroke remains uncertain. Statins 
may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. How-
ever, statins may increase the risk of intracerebral hemorrhage. We investigated the effect 
and safety of rosuvastatin in acute stroke patients.
Methods This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg 
and placebo in statin-naïve stroke patients who underwent diffusion-weighted imaging 
(DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new 
ischemic lesions on DWI at 5 or 14 days.
Results This trial was stopped early after randomization of 316 patients due to slow enroll-
ment. Among 289 patients with at least one follow-up imaging, the frequency of new isch-
emic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. pla-
cebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53–1.30). Infarct volume 
growth at 5 days (log-transformed volume change, rosuvastatin: 0.2±1.0 mm3 vs. placebo: 
0.3±1.3 mm3; P=0.784) was not different, either. However, hemorrhagic infarction or pa-
renchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging 
occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group 
(22/152, 14.5%, P=0.007). Among 314 patients with at least one dose of study medication, 
progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin 
group (1/155, 0.6% vs. 7/159, 4.4%, P=0.067). Adverse events did not differ between groups.
Conclusions The efficacy of rosuvastatin in reducing recurrence in acute stroke was incon-
clusive. However, statin use was safe and reduced hemorrhagic transformation.
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Introduction
Statins are effective in primary and secondary prevention of 
stroke.1-3 Their long-term beneficial effects may be primarily 
mediated by their lipid-lowering effects. Statins may also work 
effectively in preventing recurrence or progression during the 
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acute stage of stroke because they have antithrombotic, anti-
inflammatory, and anti-oxidative effects.4-7 
Several observational studies have suggested that statin use 
before or during the acute stage of stroke was associated with 
better functional outcome and reduced mortality.7-9 By con-
trast, intracerebral hemorrhage (ICH) developed more fre-
quently in patients treated with high-dose statins during the 
subacute or chronic stage of ischemic stroke in large random-
ized trials.2,10 Since the risk of hemorrhagic transformation is 
greater during the acute stage of stroke, statin treatment in 
acute stroke raises the concern of increased ICH risk. Howev-
er, data from randomized trials are insufficient to establish 
whether statins are effective and safe in patients with acute 
ischemic stroke.11 Furthermore, statins are not recommended 
in stroke guidelines as an agent with neuroprotective actions 
to improve outcome in acute stroke.12 Therefore, we investi-
gated the effect and safety of rosuvastatin in acute ischemic 
stroke patients.
Methods
This double-blind, placebo-controlled, randomized, multi-
center study was approved by the Ministry of Food and Drug 
Safety, Korea, and the institutional review board at each study 
center. Written informed consent was obtained from each pa-
tient. This trial (Effects of very early use of rosuvastatin in pre-
venting recurrence of ischemic stroke [EUREKA]) was regis-
tered on ClinicalTrials.gov (NCT01364220).
Study population
We enrolled patients over 20 years old diagnosed with acute 
ischemic stroke on diffusion-weighted imaging (DWI) within 
48 hours after symptom onset who had been untreated with a 
statin for the previous 3 months. Patients also should show 
any degree of stenosis on the relevant artery of infarction on 
DWI. Patients with hemorrhagic stroke, history of symptom-
atic hemorrhagic stroke, high-risk cardiac sources of embo-
lism, or stroke of other determined etiology were excluded. 
Other exclusion criteria are described in Supplementary data. 
The modified intention-to-treat population consisted of pa-
tients who underwent a baseline magnetic resonance imaging 
(MRI), had triglyceride (TG) < 500 mg/dL, low-density li-
poprotein cholesterol < 190 mg/dL, and took at least one 
dose of study medication. The per-protocol (PP) population 
consisted of patients who completed scheduled MRIs without 
a major protocol violation.
Randomization, blinding, and interventions
Patients were randomized 1:1 to receive either rosuvastatin 
or placebo. Permutated-block randomization with a block size 
of 4 was generated by an independent clinical trials center 
(Severance Hospital, Yonsei University Health System, Seoul, 
Korea). After patients were screened and completed enroll-
ment, drugs were assigned a unique study number, selected 
sequentially from the central randomization list that corre-
sponded to the treatment pack, and allocated in a double-
blind manner. The drug was administered within 18 hours af-
ter baseline MRI and then daily during the 14-day treatment 
period. Patients received either one 20-mg tablet or a placebo 
tablet, once daily.
Sample size
We hypothesized that, compared to placebo, rosuvastatin 
would reduce the occurrence of new ischemic lesions on MRI 
by 30%. To test our hypothesis, assuming a type I error of 5% 
and a power of 80%, sample sizes were calculated as 260 in 
each group. The proportion in the rosuvastatin group was as-
sumed to be 0.40 under the null hypothesis and 0.28 under 
the alternative hypothesis, based on a previous study that rec-
ognized new ischemic lesions on DWI in 34%-47.4% of pa-
tients during the first week after baseline DWI taken within 
24 hours after symptom onset.13,14 The test statistic used was 
the 2-sided Fisher’s exact test. Assuming a drop-out rate of 
5%, the total number of patients needed was 547. 
Imaging protocol 
To be eligible, patients underwent DWI, fluid attenuated in-
version recovery, gradient-recalled echo (GRE), and magnetic 
resonance (MR) angiography that included both the circle of 
Willis and neck vessels at baseline using a 1.5 T or 3.0 T MR 
scanner. Computed tomography (CT) angiography was also 
allowed. The follow-up imaging schedule included DWI, 
GRE, and fluid attenuated inversion recovery at 5 ± 1 days and 
14 ± 2 days using the same MR scanner. The images were 
saved in Digital Imaging and Communications in Medicine 
(DICOM) format and sent to the independent clinical trials 
center for review of adequacy and analyses. 
Adjudication of images
Two stroke neurologists blinded to clinical and group infor-
mation reviewed angiographic images and determined the 
presence of relevant artery stenosis in ischemic lesions on 
DWI. In cases of discrepancy between the reviewers, the deci-
sion was made by a third reviewer (a neuroradiologist). The 
reviewers also measured the degree of stenosis of the relevant 
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artery based on methods used in the North American Symp-
tomatic Carotid Endarterectomy Trial for extracranial arteries 
and the Warfarin and Aspirin for Symptomatic Intracranial 
Arterial Stenosis trial for intracranial arteries15,16 and catego-
rized stenosis as ≥ 50% or < 50%.
Outcomes
Imaging outcomes were assessed by 2 reviewers blinded to 
clinical and group information. The primary outcome was oc-
currence of a new ischemic lesion on DWI or fluid attenuated 
inversion recovery at 5 or 14 days. The secondary outcomes 
were the volume change of ischemic lesions and the percent 
improvement in National Institute of Health Stroke Scale 
(NIHSS) at 5 days and 14 days. The safety outcome included 
adverse events, laboratory results, and the presence of any in-
tracranial hemorrhagic transformation on GRE, which in-
Figure 1. Trial profile. CK, creatine kinase; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone; mITT, modified intention-to-treat population; 
MRI, magnetic resonance imaging; PP, per-protocol population; DWI, diffusion-weighted imaging.
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cluded hemorrhagic infarction (HI) and parenchymal hemor-
rhage based on European Cooperative Acute Stroke Study 
definitions.17 In case of a discrepancy in the presence of new 
lesions or hemorrhagic transformation, conclusions were 
reached by consensus. The volume of infarctions was mea-
sured on DWI in a semi-automatic manner using Xelis soft-
ware (Infinitt, Seoul, Korea). The intraclass correlation coeffi-
cient between the reviewers for log-transformed volume mea-
surements was 0.99. The percent improvement was defined as 
([NIHSS at 5 days or 14 days – NIHSS at baseline]/NIHSS 
at baseline) × 100.18 
Details of the conduction of study are provided in Supple-
mental data.
Statistical analysis
The efficacy outcome was compared based on the modified 
intention-to-treat and PP population. Safety was assessed in 
all patients who took at least one dose of study medication. 
We used the χ2 test with continuity correction to compare the 
occurrence of newly developed DWI lesion, the independent 
sample t test to compare the percent improvement in NIHSS, 
and the mixed-effect model to compare the change in log-
transformed DWI lesion volume between the rosuvastatin 
and placebo groups. The χ2 test or Fisher’s exact test was per-
formed to compare safety outcomes. Statistical analyses were 
performed using SAS statistical software, version 9.2 (SAS in-
stitute Inc., Cary, NC). Data are presented as number (%) or 
mean ± standard deviation. Two-sided P values < 0.05 were 
considered statistically significant.
Results
Baseline characteristics
A total of 28 centers in Korea participated in this study, and 
25 centers enrolled at least 1 patient. Among 318 patients en-
rolled, 316 patients met inclusion criteria and were randomized, 
and 314 took at least one dose of study medication (155 in the 
rosuvastatin group and 159 in the placebo group). Among 
them, the primary outcome was assessed in 289 patients (Fig-
ure 1). Baseline demographic characteristics were similar be-
tween the groups except total cholesterol and low-density lipo-
protein cholesterol levels, which were higher in the rosuvastatin 
group (Table 1, Supplemental Table 1). Characteristics of the 
patients whose primary outcome was not assessed are provided 
in as a Supplemental Table 2.
Efficacy outcomes
Efficacy was compared in the modified intention-to-treat 
Table 1. Baseline characteristics of the rosuvastatin and placebo groups
Rosuvastatin
(n = 155) 
Placebo
(n = 159) P value
Demographics
   Sex (male) 87 (56.1) 101 (63.5) 0.222
   Age (year) 65.4 ± 12.3 64.6 ± 11.3 0.564
   Body mass index (kg/m2) 23.8 ± 3.1 24.1 ± 3.0 0.417
   Abdominal circumference (cm) 86.2 ± 9.4 87.2 ± 9.3 0.388
Past history
   Hypertension 104 (67.0) 102 (64.1) 0.667
   Diabetes mellitus 50 (32.2) 51 (32.0) 1.000
   Hypercholesterolemia 24 (15.4) 26 (16.3) 0.955
   Smoking 72 (46.4) 67 (42.1) 0.512
   Coronary artery occlusive disease 1 (0.6) 4 (2.5) 0.371
   Peripheral artery occlusive disease 2 (1.2) 0 (0.0) 0.243
   Previous stroke 16 (10.3) 13 (8.1) 0.644
Concomitant medication
   Antihypertensive 67 (43.2) 73 (45.9) 0.715
   Antiplatelet 0.677
      Aspirin 39 (25.1) 39 (24.5)
      Clopidogrel 9 (5.8) 10 (6.2)
      Aspirin and clopidogrel 88 (56.7) 92 (57.8)
      Aspirin and cilostazol 5 (3.2) 9 (5.6)
      Aspirin, clopidogrel, and cilostazol 14 (9.0) 9 (5.6)
   Anticoagulant 0 (0.0) 1 (0.6) 1.000
   Lipid-lowering drug (other than statin) 2 (1.2) 1 (0.6) 0.619
   Diabetes mellitus drug 34 (21.9) 35 (22.0) 1.000
   Nonsteroidal anti-inflammatory drug 8 (5.1) 13 (8.1) 0.399
   Intravenous tissue plasminogen 
      activator
4 (2.5) 5 (3.1) 1.000
Log-transformed baseline 
   diffusion-weighted imaging  
   volume (mm3)
6.7 ± 1.9 6.8 ± 2.0 0.761
Baseline National Institute of Health 
   Stroke Scale 
3 [1-6] 3 [2-5.3] 0.713
Degree of stenosis 0.703
   No stenosis 12 (7.7) 12 (8.8)
   < 50% 52 (36.4) 56 (38.6)
   50%-99% 47 (32.9) 53 (36.6)
   Occlusion 44 (30.8) 36 (24.8)
Lab
   White blood cells ( × 103/μL) 7.96 ± 89.2 7.48 ± 84.3 0.929
   Neutrophils ( × 103/μL) 6.24 ± 1.6 6.13 ± 1.74 0.616
   Hemoglobin (g/dL) 14 ± 1.6 14 ± 1.6 0.823
   Hematocrit (%) 41 ± 4.5 41.1 ± 4.4 0.817
   Platelet count ( × 103/μL) 246.3 ± 60.3 240.1 ± 65.5 0.296
   Blood urea nitrogen (mg/dL) 15.1 ± 5.2 15.5 ± 5.6 0.575
   Creatinine (mg/dL) 0.83 ± 0.208 0.865 ± 0.253 0.244
   Fasting glucose (mg/dL) 131.2 ± 57.8 136.8 ± 57.1 0.256
   Albumin (g/dL) 4.1 ± 0.34 4.14 ± 0.36 0.302
   Uric acid (mg/dL) 5.06 ± 1.36 5.06 ± 1.53 0.770
   high sensitivity C-reactive protein (mg/dL) 2.517 ± 7.111 2.114 ± 6.794 0.491
   Uric acid (mg/dL) 5.06 ± 1.36 5.06 ± 1.53 0.770
   high sensitivity C-reactive protein (mg/dL) 2.517 ± 7.111 2.114 ± 6.794 0.491
Values are number (%), mean ± standard deviation, or median [interquartile 
range].
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population (137 patients in the rosuvastatin group and 152 
patients in the placebo group). New ischemic lesions on DWI 
were observed less frequently in the rosuvastatin group (27 
patients [19.7%]) than in the placebo group (36 patients 
[23.6%]), but the difference was not statistically significant 
(absolute difference 3.9%, relative risk [RR] 0.83, 95% confi-
dence interval [CI] 0.53-1.30, P = 0.500) (Figure 2A). Infarc-
tion volumes on DWI increased at 5 days and then decreased 
at 14 days in both groups. Infarct volume growth at 5 days 
(log-transformed volume change, rosuvastatin: 0.2 ± 1.0 mm3 
vs. placebo: 0.3 ± 1.3 mm3; P = 0.784) and percent improve-
ment in NIHSS (rosuvastatin vs. placebo: 36.6 ± 56.7 vs. 27.1 
± 90.8 at 5 days, P = 0.282 and 51.4 ± 51.6 vs. 42.7 ± 91.5 at 14 
days, P = 0.315) were not different. 
Safety outcomes
Of 314 patients, 3 in the placebo group (1.9%) and none in 
the rosuvastatin group demonstrated clinical recurrence of 
ischemic stroke (P = 0.248). Progression or clinical recurrence 
of stroke was reported as a serious adverse event in 7 patients 
(4.4%) in the placebo group, but in only 1 patient (0.6%) in 
the rosuvastatin group (P = 0.067). The frequency of adverse 
events did not differ between the groups (Table 2). 
On GRE, HI was observed in 6 patients at baseline (5/155 
[3.2%] in the rosuvastatin and 1/159 [0.65] in the placebo 
groups). Occurrence of any new intracranial hemorrhagic 
transformation (HI, parenchymal hemorrhage, or subarach-
noid hemorrhage) or aggravation of pre-existing HI1 at base-
line (defined as conversion to HI2 or parenchymal hemor-
rhage) was assessed in 289 patients with available GRE at 5 or 
14 days. Any new HI was observed less frequently in the rosuv-
astatin group (6/137, 4.4%) than in the placebo group (22/ 
152, 14.5%) (P = 0.007). In the rosuvastatin group, 1 patient 
developed parenchymal hemorrhage (P = 0.478), and 1 patient 
developed focal cortical subarachnoid hemorrhage on GRE 
(P = 0.478), both of whom were asymptomatic (Table 3). 
Post-hoc subgroup analysis
We compared the occurrence of a new ischemic lesion on 
DWI in patients with relevant artery stenosis ≥ 50%. New 
Figure 2. New ischemic lesions on diffusion-weighted imaging in the modified intention-to-treat population (A) and per-protocol population (B).
A
B
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ischemic lesions were found in 19 of 83 patients (22.9%) in 
the rosuvastatin group and 25 of 87 patients (28.7%) in the 
placebo group (RR, 0.80; 95% CI, 0.48-1.33; P = 0.387). 
Twenty of 78 patients (25.6%) in the rosuvastatin group and 
26 of 80 patients (32.5%) in the placebo group with multiple 
lesions on baseline DWI had new lesions (RR, 0.79; 95% CI, 
0.48-1.29; P = 0.346) (Figure 2A). 
PP Population
A total of 118 patients in the rosuvastatin group and 129 pa-
tients in the placebo group were included for the PP population 
(Figure 1). New ischemic lesions were found in 24 patients 
(20.3%) in the rosuvastatin group and 34 patients (26.3%) in 
the placebo group (RR 0.77; 95% CI, 0.49-1.22, P = 0.335) 
(Figure 2B). In the subgroup with relevant artery stenosis 
≥ 50%, new ischemic lesions were detected in 17 of 79 patients 
(21.5%) in the rosuvastatin group and 24 of 78 patients 
(30.8%) in the placebo group (RR, 0.70; 95% CI 0.41–1.20; 
P = 0.192). In the subgroup with multiple lesions, new ischemic 
lesions were observed in 17 of 69 (24.8%) patients in the rosu-
vastatin group and 25 of 69 (36.2%) patients in the placebo 
group (RR 0.68; 95% CI, 0.41–1.14; P = 0.145) (Figure 2B).
Discussion
This study was inconclusive to prove the hypothesis that 
rosuvastatin may effectively reduce early recurrence of new 
ischemic lesions, probably due to insufficient sample size. We 
could not include a sufficient number of patients because of 
slow enrollment. Despite insufficient evidence that use of a 
statin is effective or safe in acute ischemic stroke, investigators 
were reluctant to administer placebo, since statin use on dis-
charge became a performance measure for primary stroke 
center certification.19 However, a non-significant trend for less 
frequent appearance of new ischemic lesions on DWI or pro-
gression or clinical recurrence of stroke was observed in the 
rosuvastatin group. Thus, our findings support previous ob-
servational studies showing a benefit of statins in the acute 
stage of stroke.7,8
Previous randomized trials using statins in acute stroke in-
cluded small numbers of patients and showed no clinical ef-
fect or even worse outcomes after statin treatment.20-22 Serial 
MRIs were used to determine outcomes in this study. Defin-
ing clinical recurrence of stroke is sometimes difficult during 
the acute stage because pre-existing symptoms often fluctuate 
or progress. Many ischemic lesions that are recognized on 
Table 2. Adverse events 
Rosuvastatin
(n = 155) 
Placebo 
(n = 159) P value
Any AE 88 (56.8) 87 (54.7) 0.800
Any SAE 4 (2.6) 8 (5.0) 0.379
   SAE in nervous system 2 (1.3) 8 (5.0) 0.104
      Progression or clinical recurrence of 
         stroke*
1 (0.6) 7 (4.4) 0.067
      Brain herniation 0 (0.0) 1 (0.6) 1.000
      Intracerebral hemorrhage 1 (0.6) 0 (0.0) 0.494
   SAE in cardiac system 2 (1.2) 1 (0.6) 0.619
      Atrial fibrillation 1 (0.6) 0 (0.0) 0.494
      Chest discomfort 0 (0.0) 1 (0.6) 1.000
      Myocardial infarction 1 (0.6) 0 (0.0) 0.494
   SAE in gastrointestinal system 0 (0.0) 1 (0.6) 1.000
      Upper gastrointestinal bleeding 0 (0.0) 1 (0.6) 1.000
Any AE resulting in discontinuation of 
   study drug
5 (2.1) 4 (1.9) 0.539
Any AE with incidence of ≥ 5%
   Constipation 13 (8.4) 15 (9.4) 0.726
   Headache 9 (5.8) 15 (9.4) 0.319
   Progression or clinical recurrence of 
      stroke†
11 (7.1) 13 (8.2) 0.883
    Coronary artery occlusive disease 16 (10.3) 12 (7.5) 0.506
   Hypertension 12 (7.7) 14 (8.8) 0.891
Musculoskeletal AE
   Myalgia 3 (1.9) 4 (2.5) 1.000
   Myopathy 0 (0.0) 0 (0.0) 1.000
   Rhabdomyolysis 0 (0.0) 0 (0.0) 1.000
Laboratory values
   CK elevation > 3 × ULN 0 (0.0) 0 (0.0) 1.000
   Aspartate aminotransferase or alanine 
      aminotransferase elevation > 3 × ULN
0 (0.0) 0 (0.0) 1.000
Death 1 (0.4) 1 (0.5) 1.000
Values are number (%).
*Two patients with clinical recurrent stroke were included; †Three patients 
with clinical recurrent stroke (including two patients reported in SAE) were in-
cluded.
AE, adverse event; SAE, serious adverse event; CK, creatine kinase; ULN, upper 
limit of the normal range.
Table 3. Occurrence of intracranial hemorrhagic transformation on gradi-
ent-recalled echo (GRE)
Rosuvastatin 
(n = 137)
Placebo 
(n = 152) P value
HI1 2 (1.4) 15 (9.9) 0.002
HI2 2* (1.4) 7† (4.6) 0.177
PH1 1 (0.7) 0 (0.0) 0.478
PH2 0 (0.0) 0 (0.0)
Radiological subarachnoid hemorrhage 1 (0.7) 0 (0.0) 0.478
Any hemorrhagic transformation 6 (4.3) 22 (14.5) 0.007
Values are number (%).
Hemorrhagic transformation was categorized into small petechial hemorrhagic 
infarction (HI1), confluent petechial HI (HI2), small parenchymal hemorrhage 
(PH1, < 30% of infarct, mild mass effect), and large PH (PH2, > 30% of infarct, 
marked mass effect).17 
*including 1 patient who had HI-1 on baseline GRE and HI-2 on follow-up GRE.
†including 1 patient who had HI-1 on baseline GRE and HI-2 on follow-up GRE, 
4 patients who had HI-1 on 5-day GRE and HI-2 on 14-day GRE.
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DWI during the acute stage of stroke are clinically silent, but 
they are direct surrogate markers of recurrence. Ischemic inju-
ry progresses during the acute stage of infarctions23 and may 
cause growth of infarct volume. By using MRI surrogate mark-
ers such as DWI and GRE, subclinical occurrence of ischemic 
and expansion of ischemic lesions as well as hemorrhagic out-
comes might be assessed accurately.
In this study, new ischemic lesions in the placebo group de-
veloped less often than expectation which was assumed based 
on previous reports.13,14 This might be partly ascribed to the 
high frequency of use with dual or triple antiplatelet agents 
(about 75%) in this study population. We hypothesized that 
the use of statins could reduce the risk of early recurrence of 
either symptomatic or asymptomatic ischemic lesions and ex-
pansion of ischemic lesions in acute stroke. This was because 
antithrombotic and anti-inflammatory effects of statins have 
been demonstrated in many experimental studies. Statins also 
play a beneficial role in stabilizing atherosclerotic plaques.6,24 
In the subgroup analysis of our trial, the RR reduction of new 
DWI lesion occurrence in the rosuvastatin group was greater 
in patients who were more likely to have had an atherothrom-
botic infarction, such as a 20% reduction in patients with rele-
vant artery stenosis ≥ 50% and 21% reduction in those with 
multiple lesions in the territory of relevant artery stenosis. In 
the PP population (excluding patients without relevant artery 
stenosis after assessment), the difference was much greater. 
Although it is possible that statins are more effective in the 
prevention of stroke with an atherothrombotic mechanism, 
this hypothesis was inconclusive in our study.
In this study, rosuvastatin 20 mg was safe in that there were 
no differences in the development of adverse events. Notably, 
the occurrence of HI on GRE was remarkably reduced in the 
rosuvastatin group. In the Stroke Prevention by Aggressive 
Reduction in Cholesterol Levels trial, atorvastatin 80 mg in-
creased the risk of ICH (hazard ratio, 1.68; 95% CI 1.09-
2.59),2 and in the Heart Protection Study, simvastatin 40 mg 
was associated with approximately 2-fold increased risk of 
ICH in patients with prior stroke.10 However, statin use was 
not associated with ICH in a large cohort study in patients 
with recent ischemic stroke,25 and in a meta-analysis of prima-
ry and secondary prevention studies of statins.26,27 Our find-
ings suggest that statin use in the acute stage of stroke may 
protect against microvascular (capillary) damage and prevent 
HI. Matrix metalloproteinase-9 is a key proteinase that medi-
ates HI by disrupting microvascular integrity.28 Statins reduce 
expression of matrix metalloproteinase-9 in endothelial cells, 
astrocytes, and human plasma.29,30 Thus, the protective effect 
of statins against occurrence of HI might be in part mediated 
by inhibiting matrix metalloproteinase-9. 
This study has several limitations. First, this study did not 
include patients with cardioembolic sources and was con-
ducted in one Asian country. Therefore, our results should be 
interpreted with caution. Second, the median NIHSS of the 
study population at screening was 3, which suggests that en-
rolled patients had rather milder stroke. Although we assessed 
the outcome in the subgroup with significant stenosis of the 
relevant artery, this might affect the outcome such as the fre-
quency of progression or recurrence of stroke. Furthermore, 
the primary outcome of this trial was not clinical stroke recur-
rence, but imaging-based recurrent ischemic lesions. As a re-
sult, the data of clinical stroke recurrence was captured based 
on the investigators’ reports of adverse events. Finally, this 
study was stopped early due to slow enrollment, which result-
ed in underpowered results. 
In conclusion, by using MRI surrogate markers such as 
DWI and GRE, subclinical occurrence of ischemic as well as 
hemorrhagic outcomes may be assessed very sensitively and 
accurately with a relatively smaller sample size. Further stud-
ies are required to elucidate the potential benefit of statins in 
acute stroke patients to conclusively support the routine use 
of statins.
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SUPPLEMENTARY DATA
Exclusion criteria
The main exclusion criteria were hemorrhagic stroke or history of symptomatic hemorrhagic stroke; presence of high-risk po-
tential cardiac sources of embolism or other determined etiology of stroke based on the Trial of Org 10,172 in Acute Stroke Treat-
ment classification at the time of enrollment; known major hematologic, neoplastic, metabolic, gastrointestinal, or endocrine dys-
function; history of malignancy, except in subjects who had been disease-free > 5 years or whose only malignancy has been basal 
or squamous cell skin carcinoma; life-threatening illness indicating that the subject is not expected to survive for at least 2 years; 
secondary causes of nephrotic syndrome and/or renal dysfunction (serum creatinine > 2.0 mg/dL); uncontrolled hypertension 
defined as either a resting systolic blood pressure > 185 mmHg or resting diastolic blood pressure > 110 mmHg despite blood 
pressure lowering therapy; clinically significant heart disease likely to require coronary artery bypass surgery, cardiac transplanta-
tion, surgical repair, and/or valve replacement during the course of the study (within 14 days after enrollment); moderate or 
greater severity of congestive heart failure (New York Heart Association Class III or IV) or whose most recent determination of 
left ventricular ejection fraction was < 0.35; triglyceride level > 500 mg/dL; low-density lipoprotein (LDL) cholesterol level 
> 190 mg/dL; creatine kinase > 3 times the upper limit of normal range (ULN); aspartate aminotransferase, alanine aminotrans-
ferase, or bilirubin levels > 3 times the ULN; thyroid stimulating hormone > 1.5 times the ULN; modified Rankin scale score 4-6 
before stroke; possible need for conventional angiography, intervention, or carotid artery surgery during the course of the study; 
known serious hypersensitivity reactions to HMG-CoA reductase inhibitors; and history of myopathy.
Conduct of study
The first patient was enrolled in August 2010, and the study was scheduled to complete enrollment in August 2012. However, 
in June 2013 the study was stopped early due to slow enrollment. All patient data were recorded on standardized data-collection 
forms by an investigator or coordinator who was unaware of study-group assignments. All data were subsequently entered into a 
web-based clinical data management system and managed by an independent data management service (ADM Korea Inc., Seoul, 
Korea). 
Supplemental Table 1. Changes in lipid profiles before and after treat-
ment
Rosuvastatin (n = 155) Placebo (n = 159) P value
Total cholesterol
   Baseline 196.8 ± 37.6 185.9 ± 33.4 0.008
   Closing 125.4 ± 25.5 183.2 ± 34.6 < 0.001
   Change -69.2 ± 34.2 -3.7 ± 36.5 < 0.001
HDL cholesterol
   Baseline 44.5 ± 10.0 44.3 ± 12.3 0.603
   Closing 43.3 ± 10.6 41.9 ± 12.4 0.194
   Change -1.5 ± 9.0 -2.2 ± 12.1 0.477
LDL cholesterol
   Baseline 129.8 ± 33.0 119.9 ± 29.7 0.006
   Closing 63 ± 22.8 115.1 ± 31.3 < 0.001
   Change -63.9 ± 30.4 -5.8 ± 31.3 < 0.001
Triglyceride
   Baseline 128.3 ± 76.7 132.6 ± 65.9 0.191
   Closing 111.9 ± 51.0 165 ± 100 < 0.001
   Change -20.7 ± 73.2 29.2 ± 86.1 < 0.001
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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Supplemental Table 2. Characteristic of excluded patients from mITT  
Excluded from mITT (n = 25) Excluded from mITT (n = 25)
Excluded from mITT 
(n = 25)
Included in mITT 
(n = 289) P 
Rosuvastatin 20 mg 
(n = 18) Placebo (n = 7) P 
Demographics
   Sex (male) 14 (56.0) 174 (60.2) 0.842 9 (50.0) 5 (71.4) 0.407
   Age (year) 67.4 ± 11.8 64.8 ± 11.8 0.299 65.7 ± 11.1 71.7 ± 13.4 0.260
   Body mass index (kg/m2) 23.2 ± 3.3 24.0 ± 3.0 0.184 23.4 ± 3.1 22.5 ± 3.7 0.551
   Abdominal circumference (cm) 85.3 ± 8.2 86.8 ± 9.4 0.457 85.9 ± 7.7 83.8 ± 10.1 0.612
Past history
   Hypertension 19 (76.0) 187 (64.7) 0.357 13 (72.2) 6 (85.7) 0.627
   Diabetes mellitus 12 (48.0) 89 (30.7) 0.123 9 (50.0) 3 (42.8) 1.000
   Hypercholesterolemia 6 (24.0) 44 (15.2) 0.256 5 (27.7) 1 (14.2) 0.627
   Smoking 17 (68.0) 158 (54.6) 0.281 12 (66.6) 5 (71.4) 1.000
   Coronary artery occlusive disease 2 (8.0) 3 (1.0) 0.053 1 (5.5) 1 (14.2) 0.49
   Peripheral artery occlusive disease 1 (4.0) 1 (0.3) 0.153 1 (5.5) 0 (0.0) 1.000
   Previous stroke 6 (24.0) 23 (7.9) 0.019 4 (22.2) 2 (28.5) 1.000
Concomitant medication
   Antihypertensive 14 (56.0) 126 (43.5) 0.324 9 (50.0) 5 (71.4) 0.407
   Antiplatelet 0.913 0.735
      Aspirin 5 (20.0) 73 (25.2) 3 (16.6) 2 (28.5)
      Clopidogrel 2 (8.0) 17 (5.8) 1 (5.5) 1 (14.2)
      Aspirin and clopidogrel 16 (64.0) 164 (56.7) 12 (66.6) 4 (57.1)
      Aspirin and cilostazol 1 (4.0) 13 (4.4) 1 (5.5) 0 (0.0)
      Aspirin, clopidogrel, and cilostazol 1 (4.0) 22 (7.6) 1 (5.5) 0 (0.0)
   Anticoagulant 0 (0.0) 1 (0.3) 1.000 0 (0.0) 0 (0.0)
   Lipid-lowering drug (other than statin) 1 (4.0) 2 (0.6) 0.221 1 (5.5) 0 (0.0) 1.000
   Diabetes mellitus drug 11 (44.0) 58 (20.0) 0.010 8 (44.4) 3 (42.8) 1.000
   NSAID 3 (12.0) 18 (6.2) 0.228 2 (11.1) 1 (14.2) 1.000
   Intravenous tPA 1 (4.0) 8 (2.7) 0.531 0 (0.0) 1 (14.2) 0.28
Baseline DWI volume (mm3) 542.4 [203.5-4115.3] 710 [259.1-2803.6] 0.254 640.2 [223.7-4664.8] 221.5 [27.9-595.9] 0.049
Baseline NIHSS 4 [2-5] 3 [1-6] 0.206 3.5 [2-5] 4 [2-8] 0.544
Lab
   White blood cells ( × 103/μL) 7.898 ± 2.436 7.982 ± 2.325 0.896 8.248 ± 2.74 6.997 ± 1.075 0.296
   Neutrophils ( × 103/μL) 60.664 ± 10.556 61.921 ± 17.159 0.242 61.1 ± 10.686 59.543 ± 10.96 0.743
   Hemoglobin (g/dL) 13.480 ± 1.720 14.018 ± 1.590 0.098 13.461 ± 1.716 13.529 ± 1.867 0.936
   Hematocrit (%) 39.416 ± 4.776 41.158 ± 4.424 0.054 39.656 ± 5.024 38.8 ± 4.369 0.737
   Platelet count ( × 103/μL) 238.96 ± 74.077 243.474 ± 62.062 0.630 253.167 ± 81.4 202.429 ± 31.837 0.086
   BUN (mg/dL) 16.108 ± 5.354 15.236 ± 5.38 0.387 15.444 ± 4.93 17.814 ± 6.41 0.388
   Creatinine (mg/dL) 0.894 ± 0.296 0.844 ± 0.226 0.399 0.807 ± 0.198 1.116 ± 0.399 0.020
   Fasting glucose (mg/dL) 137.656 ± 60.42 133.711 ± 57.247 0.728 131.411 ± 47.397 153.714 ± 88.428 0.556
   Albumin (g/dL) 4.012 ± 0.461 4.127 ± 0.336 0.200 3.978 ± 0.479 4.1 ± 0.432 0.544
   Uric acid (mg/dL) 5.146 ± 1.616 5.052 ± 1.429 0.812 4.831 ± 1.609 5.957 ± 1.427 0.088
   hsCRP (mg/dL) 2.843 ± 6.94 2.266 ± 6.955 0.783 2.79 ± 7.423 2.98 ± 6.042 0.956
Values are number (%), mean ± standard deviation, or median [interquartile range].
mITT, modified intention-to-treat; NSAID, indicates nonsteroidal anti-inflammatory drug; t-PA, tissue plasminogen activator; DWI, diffusion-weighted imaging; 
NIHSS, National Institute of Health Stroke Scale; hsCRP, high sensitivity C-reactive protein; BUN, blood urea nitrogen.
